N/A N=34 Food Preference Following Bariatric Surgery
Obesity
Primary: Total Food Intake (Lunch Buffet) at 24 Months — 2540.1; 721 kJ
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=142 A Study of LAM-002A for the Prevention of Progression of COVID-19
COVID-19 Disease
Primary: Viral Load Change — -2.50; -1.99 log10 copies/mL — p=0.35
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
N/A N=78 Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Chronic Interstitial Cystitis · Bladder Pain Syndrome · Cystitis, Interstitial
Primary: Change in the Genitourinary Pain Index (GUPI) 2 Months — 6.6; 4.8 score on a scale
Phase 2 N=9 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Anemia · B-Cell Prolymphocytic Leukemia · Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Entospletinib in Combination With Obinutuzumab — 400 mg orally twice-daily
N/A N=30 Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
Phase 4 N=33 A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
Primary Immunodeficiency
Primary: Treatment-experienced Cohort: AUC of IGSC 20% Administered Weekly Assessed as: Steady-State AUC of Total IgG Over a Regular Dosing Interval (τ) — 167045.65…
Phase 1 N=20 Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
Healthy
Primary: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification…
Phase 1 N=50 A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Spesolimap in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 3380; 6960; 10300; 1580 Day times…
Phase 2 N=81 A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Osteosarcoma
Primary: Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment — 6.5; 5.5 months — p=0.0396
Phase 2 N=99 Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
Overweight and Obesity
Primary: Body Weight - Stage A — 101.7; 101.7; 94.5 Kilograms (kg)
N/A N=91 The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults
Diabetes Mellitus · Hypertension
Primary: Participant Retention (Feasibility) — 44; 45 Participants
Phase 4 N=35 EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Subjects Achieving Oral Treprostinil Dose — 23 Participants
Phase 2 N=110 Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Acute Pain · Post Operative Pain · Pain
Primary: Overall Summed Pain Intensity Difference (SPID) — 74.5; 82.4; 96.8; 50.5 score on a scale x hours — p=0.123
N/A N=24 Early Powered Mobility for Toddlers With Cerebral Palsy Using the Permobil® Explorer Mini and a Modified Ride-On Car
Cerebral Palsy
Primary: Change in Child Developmental Outcomes From Baseline to 8 Weeks — 5.8; 0.25; 3.9; 2.8 score on a scale